Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AGT0 | ISIN: CA12989J1084 | Ticker-Symbol: 74L
Frankfurt
23.01.25
15:29 Uhr
33,000 Euro
+1,000
+3,12 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
CALIAN GROUP LTD Chart 1 Jahr
5-Tage-Chart
CALIAN GROUP LTD 5-Tage-Chart
RealtimeGeldBriefZeit
32,80036,40022:58
GlobeNewswire (Europe)
230 Leser
Artikel bewerten:
(1)

Calian Group Ltd.: Calian Appoints New Regional Vice President of Defence for Europe, U.K. and NATO

Finanznachrichten News

Major-General (Ret.) Roch Pelletier joins Calian to drive continued growth and strengthen partnerships in expanding markets

OTTAWA, Ontario, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Calian Group Ltd. (TSX: CGY), announced today the appointment of Major-General (Ret.) Roch Pelletier to the role of Regional Vice President (RVP) Global Defence & Security. This newly created role addresses the growth of Calian's defence business, driven by increased global military spending, geopolitical instability and the rising demand for advanced technologies. This appointment will advance Calian's strategic business development, strengthen relationships with stakeholders, and provide operational support to drive growth and efficiencies within the region.

In his 36 years of service with the Canadian Armed Forces (CAF), Major-General Pelletier held senior command roles, including Commander of the Canadian Army Doctrine and Training Centre (CADTC) and the 5th Canadian Division. He also served as Director General of Intelligence, Operations, and Plans for the Canadian Joint Operations Command. During his military tenure he gained extensive expertise in national defence strategy, operational planning and international collaboration. He demonstrated an ability to navigate complex and challenging environments and deliver results.

"Major-General Pelletier's role underscores our commitment to growing our European and U.K. footprint and strengthening our support for NATO customers with mission-critical solutions," said Kevin Ford, Calian CEO. "His record of leadership, deep understanding of defence and global security challenges will be instrumental in advancing our mission and delivering future-proof solutions as we expand our services throughout Europe and the U.K."

In the RVP role, Major-General Pelletier will expand and strengthen international collaborations in support of advancing Calian's IT, cybersecurity and advanced training capabilities, addressing the growing demand for scalable solutions that enhance operational readiness and resilience in defence. This aligns with global priorities on defence modernization and collaboration across NATO allies to safeguard critical assets.

Learn more about Calian's mission-ready solutions tailored to meet any objective. Visit Calian Defenceto explore our capabilities.

About Calian
www.calian.com
We keep the world moving forward. Calian® helps people communicate, innovate, learn and lead safe and healthy lives. Every day, our employees live our values of customer commitment, integrity, innovation, respect and teamwork to engineer reliable solutions that solve complex challenges. That's Confidence. Engineered. A stable and growing 40-year company, we are headquartered in Ottawa with offices and projects spanning North American, European and international markets. Visit calian.comto learn about innovative healthcare, communications, learning and cybersecurity solutions.

Product or service names mentioned herein may be the trademarks of their respective owners.

Media inquiries:
media@calian.com
613-599-8600 x 2298

Investor Relations inquiries:
ir@calian.com

DISCLAIMER
Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events. Such statements are generally accompanied by words such as "intend", "anticipate", "believe", "estimate", "expect" or similar statements. Factors which could cause results or events to differ from current expectations include, among other things: the impact of price competition; scarce number of qualified professionals; the impact of rapid technological and market change; loss of business or credit risk with major customers; technical risks on fixed price projects; general industry and market conditions and growth rates; international growth and global economic conditions, and including currency exchange rate fluctuations; and the impact of consolidations in the business services industry. For additional information with respect to certain of these and other factors, please see the Company's most recent annual report and other reports filed by Calian with the Ontario Securities Commission. Calian disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance can be given that actual results, performance or achievement expressed in, or implied by, forward-looking statements within this disclosure will occur, or if they do, that any benefits may be derived from them.

Calian · Head Office · 770 Palladium Drive · Ottawa · Ontario · Canada · K2V 1C8
Tel: 613.599.8600 · Fax: 613-592-3664 · General info email: info@calian.com


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.